Ascentage Pharma Group International (AAPG) Q4 2025 Earnings Call Transcript

Operator

Good day, everyone, and welcome to Ascentage Pharma’s 2025 Annual Results Earnings Call. [Operator Instructions] As a reminder, today’s call is being recorded.

Thank you for joining us. I will now turn the call over to Yuly Chen, Senior Director of Investor Relations for the safe harbor statement. Yuly, please go ahead.

Yuly Chen

Thank you, operator. Please note that today’s discussion will include forward-looking statements based on our current expectations and assumptions. These statements involve risks and uncertainties and actual results may differ materially. For a full discussion of these risks, please refer to our filings and disclosures.

On today’s call, I am joined by Dr. Dajun Yang, Chairman and CEO, who will provide an overview of recent developments and 2025 annual performance. As well as Dr. Veet Misra, CFO, who will go through the financial highlights. The presentation will then be followed by a Q&A session. During the Q&A session, the team will be joined by Dr. Yifan Zhai, Chief Medical Officer; Dr. Shaomeng Wang, Cofounder, Chief Scientific Adviser, Dr. Zhichao Si, Head of Commercial, I will now turn the call over to Dr. Yang.

Dajun Yang
Co-Founder, Chairman & CEO

Thank you. Good morning. I’m Dajun Yang, Chairman and CEO of the company. Today, I’m very